NCT06301464

Active Not Recruiting

Pepsinogen II and Helicobacter Pylori Test in Gastric Cancer

Seoul National University Bundang Hospital Source

Compare

Other study identifiers

Sponsor study identifier

B-2003-603-103

Study Type

observational

Estimated enrollment

24,000

Locations

1 country

Sites

1

Timeline

Study Start

March 1, 2003

Actual (reported)

Primary Completion

December 31, 2024

Estimated (date passed)

This estimate has passed. The registry has not confirmed an actual date for this milestone.

Study Completion

December 31, 2025

Estimated (date passed)

This estimate has passed. The registry has not confirmed an actual date for this milestone.

Brief Summary

The aim of this study to validate the role of pepsinogens in gastric cancer screening.

Registry Overview

Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.

Recruitment status: active not recruiting
Estimated enrollment: 24,000 participants
Study completion date: December 31, 2025
Estimated (date passed)
This estimate has passed. The registry has not confirmed an actual date for this milestone.
Listed locations: 1 countries · 1 sites

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.

Study Start
March 1, 2003
Actual (reported)
First Submitted
March 2, 2024
Actual (reported)
First Posted
March 8, 2024
Actual (reported)
Primary Completion
December 31, 2024
Estimated (date passed)
This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
December 31, 2025
Estimated (date passed)
This estimate has passed. The registry has not confirmed an actual date for this milestone.

Last Updated: November 29, 2024
Status Verified: November 2024
Last Update Submitted: November 26, 2024

Conditions

Gastric Cancer

Keywords

Gastric cancerPepsinogenHelicobacter pylori

Outcome Measures

Primary Outcomes (1)

The level of serum pepsinogens
To compare the level of serum pepsinogens between the two groups
At the time of enrollment

Study Arms (2)

Patients with gastric neoplasms

Normal control

Normal control without gastric neoplasms

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersYes

Age GroupsAdult (18-64), Older Adult (65+)

Sampling MethodNon-Probability Sample

Study Population

Subjects who have undergone a blood test for serum pepsinogens and anti-H. pylori antibody, have undergone an esophagogastroduodenoscopy test three months before and after the blood test, have no other reason for exclusion, and have agreed to participate in the study

You may qualify if:

Who undergoes serum pepsinogens and anti-H. pylori antibody tests, and esophagogastroduodenoscopy during a health-screening examination at Seoul National University Hospital Gangnam center (SNUHGC) or Seoul National University Bundang Hospital (SNUBH)

Sponsors & Collaborators

Seoul National University Bundang Hospital
Otherlead

Study Sites (1)

Seoul National University Bundang Hospital

Seongnam-si, Gyeonggi-do, 463-707, South Korea

Biospecimen

Retention: SAMPLES WITHOUT DNA

Serum pepsinogens and anti-H. pylori antibody

MeSH Terms

Conditions

Stomach Neoplasms

Condition Hierarchy (Ancestors)

Gastrointestinal NeoplasmsDigestive System NeoplasmsNeoplasms by SiteNeoplasmsDigestive System DiseasesGastrointestinal DiseasesStomach Diseases

Study Officials

Nayoung Kim, M.D., Ph.D.
Seoul National University Bundang Hospital
PRINCIPAL INVESTIGATOR

Study Design

Study Type: observational
Observational Model: CASE CONTROL
Time Perspective: CROSS SECTIONAL
Target Duration: 1 Year
Sponsor Type: OTHER
Responsible Party: PRINCIPAL INVESTIGATOR
PI Title: Professor

Study Record Dates

First Submitted

March 2, 2024

First Posted

March 8, 2024

Study Start

March 1, 2003

Actual (reported)

Primary Completion

December 31, 2024

Estimated (date passed)

NCT00343668

S-1 and Irinotecan Combination Chemotherapy for Advanced Gastric Cancer

Phase 2Unknown

NCT00546468

Clinical Study on Laparoscopic Gastrectomy for Early Gastric Cancer (COACT_0301)

Phase 3Completed

NCT00296335

Trial of Adjuvant Chemotherapy for Gastric Cancer

Phase 3Completed

NCT00278863

Capecitabine Versus S-1 in Elderly Advanced Gastric Cancer (AGC): Randomized Trial

Phase 2Completed

NCT03046745

Gastric Cancer Registry for Epidemiology and Molecular Risk Factor

Unknown

NCT00452751

Comparison of Laparoscopic Versus Open Gastrectomy for Gastric Cancer: A Prospective Randomized Trial

Phase 3Unknown

You may not qualify if:

Who do not receive serum pepsinogens or anti-H. pylori antibody studies
Who do not receive esophagogastroduodenoscopy within 3 months before or after the date of serum pepsinogens and anti-H. pylori antibody tests
Subjects with recent proton-pump inhibitor therapy 1 month prior to enrollment
Subjects with prior history of gastrectomy
Subjects with upper gastrointestinal neoplasms other than gastric adenoma/adenocarcinoma
Subjects who do not agree to participate in the study or withdraw his/her consent

Contact the study team to confirm eligibility.

This estimate has passed. The registry has not confirmed an actual date for this milestone.

Study Completion

December 31, 2025

Estimated (date passed)

This estimate has passed. The registry has not confirmed an actual date for this milestone.

Last Updated

November 29, 2024

Record last verified: 2024-11

Data Sharing

IPD Sharing: Will not share

Source record

Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: ClinicalTrials.gov.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: NCT06301464
Data provider: ClinicalTrials.gov
Source updated: 2024-11-29
Normalization version: ctgov-legacy-1

Open registry record

Source retrieved: 2026-10-25 22:21:06 UTC

Locations

KR(1)

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Study Arms (2)

Patients with gastric neoplasms

Normal control

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

Biospecimen

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations